Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 3/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.31 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17079907 | 0.74 | GAA (0.35) | ALDH1A1GAAHTTPAX8MEN1 | |
| SCHEMBL29227046 | 0.74 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL20734815 | 0.74 | MAOB (0.36) | MEN1KMT2A | |
| SCHEMBL20734816 | 0.74 | MAOB (0.36) | MEN1KMT2A | |
| SCHEMBL20734845 | 0.70 | CNR2 (0.39) | ALDH1A1GAAMEN1KMT2A | |
| SCHEMBL20734844 | 0.70 | CNR2 (0.39) | ALDH1A1GAAMEN1KMT2A | |
| SCHEMBL20735040 | 0.69 | SMN1; SMN2 (0.37) | ALDH1A1HTTKMT2ALMNACYP3A4 | |
| SCHEMBL20734938 | 0.69 | SMN1; SMN2 (0.37) | ALDH1A1HTTKMT2ALMNACYP3A4 | |
| SCHEMBL12291600 | 0.66 | AR (0.33) | ABCG2 | |
| SCHEMBL163425 | 0.65 | MEN1 (0.41) | GAAHTTPAX8MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170239216-A1 | SMALL MOLECULE INHIBITORS OF N-TERMINUS ACTIVATION OF THE ANDROGEN RECEPTOR | THE UNITED STATES GOVERNMENT | 2017-08-24 | — | — | US | disclosed |
| US-9487479-B2 | Small molecule inhibitors of N-terminus activation of the androgen receptor | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2016-11-08 | — | — | US | disclosed |
| US-9487479-B2 | Small molecule inhibitors of N-terminus activation of the androgen receptor | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2016-11-08 | — | — | US | disclosed |
| US-9487479-B2 | Small molecule inhibitors of N-terminus activation of the androgen receptor | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2016-11-08 | — | — | US | disclosed |
| EP-2331501-B1 | SMALL MOLECULE INHIBITORS OF N-TERMINUS ACTIVATION OF THE ANDROGEN RECEPTOR | BRITISH COLUMBIA CANCER AGENCY (CA) | 2016-07-20 | — | — | EP | disclosed |
| EP-2331501-B1 | SMALL MOLECULE INHIBITORS OF N-TERMINUS ACTIVATION OF THE ANDROGEN RECEPTOR | BRITISH COLUMBIA CANCER AGENCY (CA) | 2016-07-20 | — | — | EP | disclosed |
| US-20110230539-A1 | Small Molecule Inhibitors of N-Terminus Activation of the Androgen Receptor | THE UNITED STATES GOVERNMENT | 2011-09-22 | — | — | US | disclosed |
| US-20110230539-A1 | Small Molecule Inhibitors of N-Terminus Activation of the Androgen Receptor | THE UNITED STATES GOVERNMENT | 2011-09-22 | — | — | US | disclosed |
| US-20110230539-A1 | Small Molecule Inhibitors of N-Terminus Activation of the Androgen Receptor | THE UNITED STATES GOVERNMENT | 2011-09-22 | — | — | US | disclosed |
| WO-2010020055-A1 | SMALL MOLECULE INHIBITORS OF N-TERMINUS ACTIVATION OF THE ANDROGEN RECEPTOR | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170239216-A1 | SMALL MOLECULE INHIBITORS OF N-TERMINUS ACTIVATION OF THE ANDROGEN RECEPTOR | AR, KLK3, NR5A1 | ALDH1A1 2692/4885GAA 3268/4885HTT 4834/4885 |
| US-20110230539-A1 | Small Molecule Inhibitors of N-Terminus Activation of the Androgen Receptor | AR, KLK3, NR5A1 | ALDH1A1 2692/4885GAA 3268/4885HTT 4834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.